Buy & Sell Wix.Com Ltd (WIX) – Wix.Com Ltd Price Today
Aura AI Summary
Key Stats
- $1.78BMarket Cap
- TechnologySector
- -55.33%3M Drawdown
- $1.35BEnterprise Value
- -Dividend Yield
- 76% Buy | 24% SellTrading Activity
- 52 daysTypical Hold Time
Wix.Com Ltd (WIX) is currently valued at a market capitalization of $1.78B, with an enterprise value of $1.35B. Over the past 52 weeks, Wix.Com Ltd has traded between a low of $40.43 and a high of $184.24, highlighting its annual price range. Over the past three months, Wix.Com Ltd has recorded a drawdown of -55.33%, reflecting recent price volatility. On average, investors hold Wix.Com Ltd for approximately 52 days, indicating typical investor behavior on the platform.
About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Most Recent News
Nyrstar publishes legal opinion on effects of company liquidation amid ongoing criminal proceedings.
Nyrstar NV released a legal opinion addressing the impact of its potential dissolution and liquidation on ongoing criminal cases and its ability to pursue claims against responsible third parties. This follows a notice from the FSMA and aims to clari...

Nyrstar releases legal advice on company dissolution and ongoing criminal case implications
Nyrstar NV has published a legal opinion from external lawyers regarding the impact of a potential company dissolution and liquidation on an ongoing criminal procedure and the company's ability to protect its rights by possibly filing claims against ...

Oblenio Bio raises $62M to advance autoimmune drug LBL-051 into clinical trials.
Oblenio Bio secured $62 million in a Series B funding round led by Pfizer Ventures to support clinical development of LBL-051, a tri-specific T-cell engager targeting autoimmune diseases. LBL-051 aims to reset the immune system by depleting B-cells a...
